GANAB and ovarian carcinoma: As a result, YTHDC1 knockdown significantly promoted ovarian cancer progression in vivo and in vitro and GANAB knockdown markedly suppressed ovarian cancer progression in vivo and in vitro, however, silencing GANAB abrogated shYTHDC1-induced tumor promotion (Figure S10A-F).